7,952 results match your criteria Mycosis Fungoides


Changes in total skin electron beam therapy modalities for mycosis fungoides: A single-centre study.

Ann Dermatol Venereol 2022 May 17. Epub 2022 May 17.

Department of Dermatology, Hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France; Inserm, U 1312, Translational Research on Oncodermatology and Orphean skin diseases, BRIC, University of Bordeaux, RIC - UMR, 33000 Bordeaux, France. Electronic address:

Background: Mycosis fungoides (MF) is a highly radiosensitive disease. Total skin electron beam therapy (TSEBT) is an effective option that may allow prolonged response for several months. Recently, a low-dose regimen (12 Gy) has been reported more frequently, with less complete response than for standard doses (36 Gy) but better safety. Read More

View Article and Full-Text PDF

Chlormethin-Gel zur Behandlung der Mycosis fungoides: Ein Expertenkonsens aus Deutschland, Österreich und der Schweiz (DACH-Region) zum Therapiemanagement.

J Dtsch Dermatol Ges 2022 May;20(5):579-588

Abteilung für Haut- und Geschlechtskrankheiten, Universitätsklinikum St. Pölten, Karl Landsteiner Privatuniversität für Gesundheitswissenschaften, St. Pölten, Österreich.

Hintergrund: Chlormethin-Gel ist in Europa zur Therapie von Patienten mit Mycosis fungoides in allen Krankheitsstadien zugelassen. Die optimalen Behandlungsregime hinsichtlich Frequenz, Dosierung, Kombinations- oder Erhaltungstherapien sind noch nicht vollständig etabliert.

Methodik: Zehn in der Erforschung und Behandlung kutaner T-Zell-Lymphome erfahrene Experten aus Deutschland, Österreich und der Schweiz (DACH-Region) wurden schriftlich zu Indikation, Anwendungsfrequenz, Beurteilung des Therapieerfolgs, Begleittherapie, Nebenwirkungen, Kombinationstherapien in späteren Krankheitsstadien, Erhaltungstherapie und Adhärenz im Rahmen der Therapie der Mycosis fungoides mit Chlormethin-Gel befragt. Read More

View Article and Full-Text PDF

Prevalence of T-cell antigen losses in mycosis fungoides and CD30-positive cutaneous T-cell lymphoproliferations in a series of 153 patients.

Pathology 2022 May 13. Epub 2022 May 13.

Department of Pathology, APHP, Henri Mondor Hospital, Creteil, France; Paris-Est Creteil University and INSERM U955 Team NFL, Creteil, France. Electronic address:

Mycosis fungoides (MF) and primary cutaneous CD30-positive T-cell lymphoproliferative disorders (CD30LPD) are the most frequent primary cutaneous T-cell lymphomas. Our objective was to study pan-T-cell antigens and PD-1 expression in a large cohort of MF and CD30LPD with a special interest in antigen losses as a diagnostic tool. We retrospectively reviewed 160 consecutive samples from 153 patients over a 3 year period, including 104 with MF and 49 with CD30LPD. Read More

View Article and Full-Text PDF

Healthcare Disparities in the Management of Indolent Mycosis Fungoides.

Cureus 2022 Apr 13;14(4):e24098. Epub 2022 Apr 13.

Dermatology, Elias Emergency University Hospital, Bucharest, ROU.

Mycosis fungoides represents the most common cutaneous T-cell lymphoma, clinically manifested with evolving skin lesions, including patches, plaques, tumors, and erythroderma. Early diagnosis remains difficult to establish because it mimics several benign skin conditions, but maintaining a high index of suspicion for the disease is essential in preventing the progression of a potentially fatal disease. We report the case of a 69-year-old female who presented in our dermatology clinic in 2018 with scaly, indurated, itchy erythematous-violaceus patches and plaques, and tumors disseminated throughout the skin evolving for nine years. Read More

View Article and Full-Text PDF

New developments in skin-directed treatments of cutaneous T-cell lymphoma.

Presse Med 2022 May 10:104125. Epub 2022 May 10.

Division of Dermatology, Rabin Medical Center-Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address:

The therapeutic approach for mycosis fungoides, the most common type of primary cutaneous T-cell lymphoma, is based mainly on the stage of the disease, and skin-directed treatment is recommended by all international guidelines as the first-line treatment in early-stage disease. Skin-directed treatments may be also given in combination with systemic therapies in early-stage mycosis fungoides patients recalcitrant to different types of skin-directed treatments, or in certain patients with high-risk features. Advanced-stage mycosis fungoides is treated mainly with systemic treatments, which may be combined with skin-directed treatments. Read More

View Article and Full-Text PDF

Low-Dose MST-16/VP-16 Combination Chemotherapy in 9 Patients with Tumor Stage Mycosis Fungoides.

Dermatology 2022 May 12:1-6. Epub 2022 May 12.

Department of Dermatology, Tokyo Medical University, Tokyo, Japan.

Background/aim: MST-16 and VP-16, both of which are topoisomerase II inhibitors, are antitumor agents regularly used to treat malignant lymphoma and small cell lung carcinoma. New therapeutic agents for tumor stage mycosis fungoides (MF) have recently been developed, but their efficacy is limited. We herein retrospectively reported the use of MST-16/VP-16 combination therapy for tumor stage MF at multiple treatment centers and examined their antitumor effect. Read More

View Article and Full-Text PDF

Evaluation of Biological Effects and Transcriptome Changes Induced by LED Based Narrow Band UVB Phototherapy.

Photochem Photobiol 2022 May 10. Epub 2022 May 10.

School of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.

Ultraviolet (UV), particularly UVB, is widely used in the treatment of skin diseases including psoriasis, atopic dermatitis, vitiligo, mycosis fungoides, and pruritus. Recently, there has been a trend of replacing broad band UVB (BB-UVB) units with narrow band UVB (NB-UVB), as studies have demonstrated that NB-UVB is more efficacious in the treatment of psoriasis. The purpose of this study is to evaluate the biological effects and transcriptome changes induced by light emitting diode based NB-UVB (NB-UVB LED) phototherapy. Read More

View Article and Full-Text PDF

Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data.

Am J Clin Dermatol 2022 May 10. Epub 2022 May 10.

Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petah Tikvah, Israel.

Background: Chlormethine gel was approved for treatment of mycosis fungoides, the most common cutaneous T-cell lymphoma, on the basis of results from study 201 and study 202. A post-hoc analysis of study 201 found interesting trends regarding improved efficacy of chlormethine gel vs ointment and noted a potential association between dermatitis and clinical response.

Objective: To expand these results by performing a post-hoc analysis of study 202. Read More

View Article and Full-Text PDF

Paediatric mycosis fungoides - characteristics, management and outcomes with particular focus on the folliculotropic variant.

J Eur Acad Dermatol Venereol 2022 May 9. Epub 2022 May 9.

Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.

View Article and Full-Text PDF

A case of mycosis fungoides effectively treated with ultraviolet light A 1-light emitting diode (UVA1-LED) phototherapy.

Photodermatol Photoimmunol Photomed 2022 May 8. Epub 2022 May 8.

Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

View Article and Full-Text PDF

Cutaneous T-cell lymphoma: diagnosing subtypes and the challenges.

Br J Hosp Med (Lond) 2022 Apr 14;83(4):1-7. Epub 2022 Apr 14.

Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

Cutaneous T-cell lymphoma is a rare type of extranodal non-Hodgkin's lymphoma that primarily affects the skin. The uncertain pathogenesis and variable clinical presentation make the diagnosis and management of cutaneous T-cell lymphoma a challenge. Cutaneous T-cell lymphoma is a chronic, relapsing illness with treatment aimed at symptomatic relief and improving patient related quality of life. Read More

View Article and Full-Text PDF

Care structure of patients with mycosis fungoides and Sézary syndrome in Germany - Care research based on SHI claims data.

J Dtsch Dermatol Ges 2022 05 2;20(5):643-651. Epub 2022 May 2.

Kyowa Kirin GmbH, Düsseldorf.

Background: Cutaneous T-cell lymphomas (CTCLs) are rare forms of non-Hodgkin's lymphoma of T-cell origin that occur mainly in the skin. The most common form is mycosis fungoides (MF), but Sézary syndrome (SS), a more aggressive form of CTCL, is another relevant subgroup. Due to the rare nature of the disease, population-based studies of the epidemiology and disease burden and insights into care delivery are limited. Read More

View Article and Full-Text PDF

Influencing Factors of Total Skin Irradiation With Helical Tomotherapy.

Front Oncol 2022 14;12:852345. Epub 2022 Apr 14.

Institute of Nuclear Medical Physics, University of Science and Technology of China, Hefei, China.

Purpose: To investigate the influencing factors of total skin irradiation (TSI) with helical tomotherapy for guiding the clinical selection of the suitable parameters and optimizing the plan quality and efficiency.

Materials And Methods: Six patients with mycosis fungoides (MF) who received TSI were retrospectively selected. They were all dressed with 5 mm thick diving suits during the CT scan and treatment as a bolus to increase the superficial dose through buildup. Read More

View Article and Full-Text PDF

The PROCLIPI international registry, an important tool to evaluate the prognosis of cutaneous T cell lymphomas.

Authors:
J J Scarisbrick

Presse Med 2022 Apr 28:104123. Epub 2022 Apr 28.

Department of Dermatology, University Hospital Birmingham, Birmingham, UK. Electronic address:

PROCLIPI is the PROgnostic Cutaneous Lymphoma International Prognostic Index Study with the main aim to produce a prognostic index in mycosis fungoides (MF) and Sezary syndrome (SS). The study prospectively collects clinical, haematological, pathological, imaging, treatment with responses, quality of life and survival data using careful predefined datasets. Patients are subject to a central review to confirm diagnosis. Read More

View Article and Full-Text PDF

Methotrexate Cutaneous Ulceration: A Systematic Review of Cases.

Am J Clin Dermatol 2022 Apr 29. Epub 2022 Apr 29.

Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, South Tower, 7th floor, Philadelphia, PA, 19104, USA.

Background: Methotrexate cutaneous ulceration is a rare methotrexate complication, and has only been described in case reports and case series.

Objective: To document patient characteristics, morphologic features, and mortality risk factors for methotrexate cutaneous ulceration.

Methods: A systematic literature review of PubMed and Embase (last date 1 November 2021) was performed with data collected from case reports and case series. Read More

View Article and Full-Text PDF

Woringer-Kolopp disease (localized pagetoid reticulosis): a systematic review.

Int J Dermatol 2022 Apr 29. Epub 2022 Apr 29.

Wayne State University School of Medicine, Detroit, Michigan, USA.

Objective: Woringer-Kolopp disease (WKD), also known as localized pagetoid reticulosis, is a rare variant of mycosis fungoides as described by the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification system for cutaneous lymphomas. Our objective was to conduct a comprehensive review that describes and evaluates patient demographics, clinical presentation, immunohistochemical findings, management, and outcomes of WKD.

Methods: The databases PubMed, Embase, and Cochrane Library were searched for relevant literature. Read More

View Article and Full-Text PDF

African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center.

Leuk Lymphoma 2022 Apr 28:1-8. Epub 2022 Apr 28.

Department of Hematology, Winship Cancer Institute, Atlanta, GA, USA.

Sézary syndrome (SS) is an aggressive cutaneous T-cell lymphoma with poor survival. We performed a retrospective review of SS patients at Emory University from 1990 to 2020. We collected data on race, clinical characteristics, therapy, and social determinants of health. Read More

View Article and Full-Text PDF

Subtlety of Granulomatous Mycosis Fungoides: A Retrospective Case Series Study and Proposal of Helpful Multimodal Diagnostic Approach With Literature Review.

Am J Dermatopathol 2022 Apr 11. Epub 2022 Apr 11.

Department of Dermatopathology, Icahn School of Medicine at Mount Sinai, New York, NY.

Abstract: Granulomatous mycosis fungoides (GMF) harbors a worse prognosis compared with classic MF and remains a significant diagnostic dilemma. We analyzed clinicopathologic, immunophenotypic, and molecular characteristics of GMF to develop a diagnostic algorithm. Our methodology involved a retrospective case series study of patients with GMF from our database between 2014 and 2020. Read More

View Article and Full-Text PDF

Chlormethine gel is effective for the treatment of skin lesions in patients with early- and late-stage mycosis fungoides in clinical practice.

J Eur Acad Dermatol Venereol 2022 Apr 26. Epub 2022 Apr 26.

1st Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University of Athens Medical School, "Andreas Sygros" Hospital for Skin Diseases, Athens, Greece.

Background: Chlormethine gel is a skin-directed therapy used for patients with mycosis fungoides (MF) that showed a favourable risk/benefit profile in a randomized clinical trial. Currently, data on chlormethine gel use in real-world settings are limited.

Objectives: The aim of this study was to assess safety and efficacy of chlormethine gel treatment in patients treated during daily clinical practice and investigate associations between response and disease stage, lesion type, mono- or combination therapy, and occurrence of dermatitis. Read More

View Article and Full-Text PDF

PD-1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome.

Cytometry B Clin Cytom 2022 05 22;102(3):189-198. Epub 2022 Apr 22.

Hematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Background: Accurate Sezary cell detection in peripheral blood of mycosis fungoides/Sezary syndrome (MF/SS) patients by flow cytometry can be difficult due to overlapping immunophenotypes with normal T cells using standard markers. We assessed the utility of programmed death-1 (PD-1/CD279), a transmembrane protein expressed in some hematopoietic cells, for identification and quantitation of circulating Sezary cells among established markers using flow cytometry.

Methods: 50 MF/SS and 20 control blood samples were immunophenotyped by flow cytometry. Read More

View Article and Full-Text PDF

Incidence and Prevalence of Skin Cancers in South Korea from 2008 to 2016: A Nation-Wide Population Based Study.

Ann Dermatol 2022 Apr 24;34(2):105-109. Epub 2022 Mar 24.

Department of Dermatology, Dankook University College of Medicine, Cheonan, Korea.

Background: In South Korea, there have been few nationwide epidemiologic studies about premalignant actinic keratosis (AK), squamous cell carcinoma (Bowen's disease), nonmelanoma skin cancer (NMSC), malignant melanoma of the skin (MM), Kaposi's sarcoma (KS), connective and soft tissue cancers, or mycosis fungoides (MF).

Objective: Using a nationwide population-based study, we attempted to measure the incidence and the prevalence of the above-mentioned tumors in South Korea.

Methods: The database we used included all claims in the Korean National Health Insurance program and the Korean Medical Aid program from 2008 to 2016. Read More

View Article and Full-Text PDF

Application of the Current Diagnostic Algorithm for Early Mycosis Fungoides to a single center cohort: Identification of challenges and suggestions to modify.

J Cutan Pathol 2022 Apr 21. Epub 2022 Apr 21.

Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA.

Background: Diagnosing early-stage Mycosis fungoides (MF) remains a significant challenge. The International Society for Cutaneous Lymphomas (ISCL) proposed an algorithm for diagnosing early MF incorporating clinical and histopathologic characteristics, as well as immunohistochemistry and molecular studies. Here we aim to examine the diagnostic utility of the ISCL algorithm. Read More

View Article and Full-Text PDF

The Treatment of Advanced-Stage Mycosis Fungoides and Sezary Syndrome: a Hematologist's Point of View.

Mediterr J Hematol Infect Dis 2022 1;14(1):e2022029. Epub 2022 Mar 1.

Department of Hematology, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Largo A. Gemelli, 8 I-00168 Rome, Italy.

Cutaneous T-cell lymphomas are a heterogeneous group of T-cell neoplasms involving the skin, the majority of which may be classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS). Mycosis fungoides (MF) is usually associated with an indolent clinical course and intermittent, stable, or slow progression of the lesions. Extracutaneous involvement (lymph nodes, blood, or less commonly other organs) or large cell transformation (LCT) may be seen in advanced-stage disease. Read More

View Article and Full-Text PDF

[Translated article] Advanced-Stage CD30 Mycosis Fungoides Treated With Brentuximab.

Actas Dermosifiliogr 2022 Apr 15. Epub 2022 Apr 15.

Servicio de Dermatología, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain.

View Article and Full-Text PDF

Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma.

Blood 2022 Apr 18. Epub 2022 Apr 18.

Stanford University, Stanford, California, United States.

Mogamulizumab is a humanized anti-CCR4 antibody approved for the treatment of mycosis fungoides and Sézary Syndrome. Despite almost universal expression of CCR4 in these diseases, most patients eventually develop resistance to mogamulizumab. We tested whether resistance to mogamulizumab is associated with loss of CCR4 expression. Read More

View Article and Full-Text PDF

The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region).

J Dtsch Dermatol Ges 2022 05 15;20(5):579-586. Epub 2022 Apr 15.

Department of Dermatology and Venereology, University Hospital St. Pölten, Karl Landsteiner University of Health Sciences, St. Pölten, Austria.

Background: In Europe chlormethine gel is licensed for the management of patients with mycosis fungoides of all stages. However, the optimal regimen regarding frequency and dosing as well as combination and maintenance therapy is not well established.

Methods: Ten experts experienced in research and management of cutaneous T-cell lymphomas from Germany, Austria, and Switzerland (DACH region) were asked in written form to report on indication for chlormethine gel, frequency of use, monitoring, concomitant therapies, adverse effects, combination therapies in later stages of the disease, maintenance therapy, and adherence to this therapy for mycosis fungoides. Read More

View Article and Full-Text PDF